Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
BioXcel Therapeutics
BTAI
$34.9M
| $3.94M | ﹤0.01% |
8,123
+1,701
| +26% | +$748K |
|
2477
IES Holdings
IESC
$14.9B
| $3.94M | ﹤0.01% |
86,222
-55,961
| -39% | -$2.72M |
|
2478
4D Molecular Therapeutics
FDMT
$609M
| $3.92M | ﹤0.01% |
145,154
+81,934
| +130% | +$2.34M |
|
2479
JD.com
JD
$39.6B
| $3.91M | ﹤0.01% |
54,178
-953,039
| -95% | -$70.3M |
|
|
UBA
2480
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $3.91M | ﹤0.01% |
206,532
-114
| -0.1% | -$2.18K |
|
2481
Keros Therapeutics
KROS
$211M
| $3.9M | ﹤0.01% |
98,544
+19,960
| +25% | +$710K |
|
2482
Global Industrial
GIC
$1.49B
| $3.88M | ﹤0.01% |
102,533
-731
| -0.7% | -$27.5K |
|
2483
Alpha and Omega Semiconductor
AOSL
$916M
| $3.88M | ﹤0.01% |
123,798
+11,392
| +10% | +$316K |
|
2484
Mercado Libre
MELI
$92.7B
| $3.88M | ﹤0.01% |
2,311
+4
| +0.2% | +$6.93K |
|
2485
Phathom Pharmaceuticals
PHAT
$743M
| $3.88M | ﹤0.01% |
120,871
+13,751
| +13% | +$457K |
|
|
ALX
2486
Alexander's
ALX
$1.4B
| $3.88M | ﹤0.01% |
14,882
+110
| +0.7% | +$29.4K |
|
2487
IMAX
IMAX
$2.92B
| $3.87M | ﹤0.01% |
203,761
+47,736
| +31% | +$792K |
|
2488
York Water
YORW
$536M
| $3.87M | ﹤0.01% |
88,517
-613
| -0.7% | -$29.4K |
|
2489
Talos Energy
TALO
$2.58B
| $3.86M | ﹤0.01% |
280,457
+49,131
| +21% | +$599K |
|
2490
Cullinan Oncology
CGEM
$1.26B
| $3.85M | ﹤0.01% |
170,744
+81,045
| +90% | +$2.17M |
|
2491
Precision BioSciences
DTIL
$201M
| $3.85M | ﹤0.01% |
11,115
+523
| +5% | +$177K |
|
|
DHIL
2492
DELISTED
Diamond Hill
DHIL
| $3.84M | ﹤0.01% |
21,863
+1,282
| +6% | +$224K |
|
|
REVG
2493
DELISTED
REV Group
REVG
| $3.84M | ﹤0.01% |
223,792
+32,473
| +17% | +$517K |
|
|
BFS
2494
Saul Centers
BFS
$865M
| $3.83M | ﹤0.01% |
86,829
+542
| +0.6% | +$24.4K |
|
|
JOYY
2495
JOYY Inc
JOYY
$3.64B
| $3.83M | ﹤0.01% |
69,778
+1,430
| +2% | +$80.1K |
|
2496
Forrester Research
FORR
$224M
| $3.82M | ﹤0.01% |
77,494
+651
| +0.8% | +$30.5K |
|
2497
OneSpaWorld
OSW
$2.73B
| $3.81M | ﹤0.01% |
382,540
+5,290
| +1% | +$52.1K |
|
2498
Nordic American Tanker
NAT
$1.4B
| $3.8M | ﹤0.01% |
1,483,650
+281,955
| +23% | +$708K |
|
2499
International Money Express
IMXI
$353M
| $3.8M | ﹤0.01% |
227,268
+32,899
| +17% | +$551K |
|
|
ITOS
2500
DELISTED
iTeos Therapeutics
ITOS
| $3.79M | ﹤0.01% |
140,518
+43,432
| +45% | +$1.14M |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.